Entrada Therapeutics
TRDA • NASDAQ
Entrada Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Dipal Doshi, with a market cap of $500.4M.
Market Cap$500.4M
Employees159.0
CEODipal Doshi
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 7, 2026 · In 1 weekBefore Market Open · Q1 2026
Financials
Entrada Therapeutics FAQ
Common questions about Entrada Therapeutics
Entrada Therapeutics is scheduled to report earnings for Q1 2026 on May 7, 2026 before market open. Analysts estimate revenue of $2.9M.
Entrada Therapeutics has approximately 159 employees.